Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06960395 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumor Malignancies and EGFR, sponsored by Vir Biotechnology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 450
- Enrollment target
- 4
- Study locations
NCT06960395 is a Phase 1 study of Solid Tumor Malignancies and EGFR that is actively recruiting participants, run by Vir Biotechnology. The registered enrollment target is 450 participants, above the 155-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (190% higher). The trial reports 4 study locations across 4 states.
The verdict
NCT06960395, a Phase 1 study of Solid Tumor Malignancies and EGFR, is actively recruiting participants, sponsored by Vir Biotechnology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 450 participants
- Enrollment target
- 4
- Study locations
Study Summary
This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in participants with solid tumors that are known to express EGFR. The study will be conducted in the following 4 parts: * Part 1: VIR-5525 monotherapy dose escalation * Part 2: VIR-5525 monotherapy dose expansion * Part 3: VIR-5525 plus pembrolizumab dose escalation * Part 4: VIR-5525 plus pembrolizumab dose expansion
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG VIR-5525
Study Locations (4)
Arizona
- Honor Health Research Institute - Scottsdale
Texas
- MD Anderson - Houston
New South Wales
- Wollongong Hospital - Wollongong
Queensland
- Princess Alexandra Hospital - Woolloongabba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2029-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06960395
The ClinicalTrials.gov registry entry for NCT06960395 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 155-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (190% higher). The listed sponsor is Vir Biotechnology, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06960395 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Texas, New South Wales.
Frequently Asked Questions
What is clinical trial NCT06960395 about?
NCT06960395 is a clinical study titled "Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in participants with solid tumors that are known to express EGFR. The study wil...
What is the current status of trial NCT06960395?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 450 participants. The study started on 2025-07-22. Estimated completion is 2029-08.
What conditions does trial NCT06960395 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies, EGFR, EGFR Positive Solid Tumors.
What interventions are being tested in trial NCT06960395?
The interventions under investigation include: Pembrolizumab (DRUG), VIR-5525 (DRUG).
Who is sponsoring clinical trial NCT06960395?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06960395 being conducted?
This trial has 4 study locations across Arizona, Texas, New South Wales, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.